Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients

Anna Kuznetsova; Aleksey Lebedev; Konstantin Gromov; Elena Kazennova; Maurizio Zazzi; Francesca Incardona; Anders Sönnerborg; Marina Bobkova

Journal ArticleOPEN ACCESS

Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients

Kuznetsova A
Lebedev A
Gromov K
et al.

Clinical Case Reports (2022) 10(2)

DOI: 10.1002/ccr3.5373

N/ACitations

7Readers

Abstract

General consensus suggests that even singleton E138A mutations in HIV reverse transcriptase at baseline are associated with resistance to rilpivirine (RPV). We detected 11 pre‐existing E138A carriers treated with RPV in the pan European EuResist database. However, all 11 patients presented with full virological efficacy for first‐line RPV‐based ART regimens.

Cite

CITATION STYLE

APA

Kuznetsova, A., Lebedev, A., Gromov, K., Kazennova, E., Zazzi, M., Incardona, F., … Bobkova, M. (2022). Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients. Clinical Case Reports, 10(2). https://doi.org/10.1002/ccr3.5373

Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients

Abstract

Cite

Register to see more suggestions